Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others.
(Albany, United States) 'Multiple System Atrophy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market.
As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details
Request for sample report to know in detail about drugs and companies in pipeline @ Multiple System Atrophy Pipeline Outlook
Some of the key takeaways from the Multiple System Atrophy Pipeline Report:
Multiple System Atrophy Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years.
Multiple System Atrophy companies working in the treatment market are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others, are developing therapies for the Multiple System Atrophy treatment
Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years.
are expected to have a significant impact on the Multiple System Atrophy market in the coming years. In May 2025, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ('Alterity' or 'the Company'), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ATH434 for the treatment of Multiple System Atrophy (MSA). This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy.
In February 2025, H. Lundbeck A/S (Lundbeck) today announced that amlenetug has received Fast Track designation from the United States (US) Food and Drug Administration (FDA).
In December 2024, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology firm focused on creating disease-modifying therapies for neurodegenerative disorders, announced that the final participant in its ATH434-201 Phase 2 trial has completed the study. This randomized, double-blind, placebo-controlled trial targets early-stage multiple system atrophy (MSA). With this milestone reached, topline results are anticipated by late January or early February 2025.
Multiple System Atrophy Overview
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by Multiple System Atrophy autonomic dysfunction, Multiple System Atrophy parkinsonism, and Multiple System Atrophy cerebellar ataxia. Multiple System Atrophy symptoms often include orthostatic hypotension, urinary incontinence, tremors, bradykinesia, muscle rigidity, gait imbalance, and coordination problems. Multiple System Atrophy diagnosis typically relies on clinical evaluation supported by MRI findings, which may show putaminal or cerebellar atrophy, although no definitive test exists. Multiple System Atrophy pathology reveals glial cytoplasmic inclusions containing alpha-synuclein, distinguishing it from similar disorders.
Multiple System Atrophy progression is usually rapid, leading to severe disability within a few years of onset. Multiple System Atrophy treatment remains symptomatic, aiming to manage blood pressure fluctuations, motor symptoms, and urinary issues. While Multiple System Atrophy levodopa responsiveness is often poor compared to Parkinson's disease, some patients may experience temporary benefit. Multiple System Atrophy prognosis is generally poor, with an average survival of 6 to 10 years post-diagnosis.
Ongoing Multiple System Atrophy research explores neuroprotective agents and disease-modifying therapies. Multiple System Atrophy awareness is essential for early recognition and multidisciplinary care to optimize patient quality of life.
Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight
Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include:
NM-402: Neuramedy Co.,Ltd
Neuramedy Co.,Ltd PMN442: ProMIS Neurosciences
ProMIS Neurosciences ENT-01: Enterin Inc.
Enterin Inc. NC-2500: Nippon Chemiphar
Nippon Chemiphar CS10BR05: CORESTEM, Inc
CORESTEM, Inc AAV2-GDNF: Brain Neurotherapy Bio, Inc.
Brain Neurotherapy Bio, Inc. KM-819: Kainos Medicines
Kainos Medicines ATH434: Alterity Therapeutics
Alterity Therapeutics Lu AF82422: H. Lundbeck A/S
H. Lundbeck A/S Verdiperstat: Biohaven, Ltd
Biohaven, Ltd Ampreloxetine: Selecta Biosciences Inc
Selecta Biosciences Inc ION464: Ionis Pharmaceuticals, Inc
Multiple System Atrophy Route of Administration
Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Multiple System Atrophy Molecule Type
Multiple System Atrophy Products have been categorized under various Molecule types, such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Multiple System Atrophy Pipeline Therapeutics Assessment
Multiple System Atrophy Assessment by Product Type
Multiple System Atrophy By Stage and Product Type
Multiple System Atrophy Assessment by Route of Administration
Multiple System Atrophy By Stage and Route of Administration
Multiple System Atrophy Assessment by Molecule Type
Multiple System Atrophy by Stage and Molecule Type
DelveInsight's Multiple System Atrophy Report covers around 22+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies
Some of the key companies in the Multiple System Atrophy Therapeutics Market include:
Key companies developing therapies for Multiple System Atrophy are - Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.
Multiple System Atrophy Pipeline Analysis:
The Multiple System Atrophy pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies
Multiple System Atrophy Pipeline Market Drivers
Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market.
Multiple System Atrophy Pipeline Market Barriers
However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth.
Scope of Multiple System Atrophy Pipeline Drug Insight
Coverage: Global
Key Multiple System Atrophy Companies: Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others
Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd, Selecta Biosciences Inc, Ionis Pharmaceuticals, Inc, and others Key Multiple System Atrophy Therapies: NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others
NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, ION464, and others Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies
Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers
Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials
Table of Contents
1. Multiple System Atrophy Report Introduction
2. Multiple System Atrophy Executive Summary
3. Multiple System Atrophy Overview
4. Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment
5. Multiple System Atrophy Pipeline Therapeutics
6. Multiple System Atrophy Late Stage Products (Phase II/III)
7. Multiple System Atrophy Mid Stage Products (Phase II)
8. Multiple System Atrophy Early Stage Products (Phase I)
9. Multiple System Atrophy Preclinical Stage Products
10. Multiple System Atrophy Therapeutics Assessment
11. Multiple System Atrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Multiple System Atrophy Key Companies
14. Multiple System Atrophy Key Products
15. Multiple System Atrophy Unmet Needs
16 . Multiple System Atrophy Market Drivers and Barriers
17. Multiple System Atrophy Future Perspectives and Conclusion
18. Multiple System Atrophy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name:DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website:https://www.delveinsight.com/consulting
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
35 minutes ago
- National Post
Tickblaze & Databento Forge Strategic Partnership to Supercharge Institutional-Grade Quant Platforms
Article content OTTAWA, Ontario — Tickblaze, the award-winning hybrid trading platform engineered for professional quant and systematic traders, today announced a strategic data partnership with Databento, one of the fastest-growing institutional market data providers in the world. Article content Tickblaze will integrate Databento's real-time and historical market data that is widely used by top-tier quant firms. Databento provides comprehensive order book information with nanosecond timestamps and exchange-colocated feeds across equities, futures, and options. Article content 'We sought out Databento because their data infrastructure sets the institutional benchmark,' said Sean Kozak, CEO of Tickblaze. 'Combined, we offer quant funds a seamless environment for building, testing, and executing portfolio‑level strategies—solo or multi‑assets.' Article content Databento powers hundreds of quant firms, both emerging and established players with over 3,000 leading institutions and high-growth startups, direct feeds across over 50 venues, and scalable APIs that simplify onboarding. Article content Christina Qi, CEO of Databento, added: 'Tickblaze's hybrid tech stack—command‑line tools, scripting environments, and multi‑asset backtesting—is exactly the kind of platform our data is designed to complement.' Article content The partnership enables hedge funds and quant firms to access state‑of‑the‑art data and execution logic within a unified system, significantly reducing setup time and complexity. Tickblaze's platform already supports advanced analytics, order management, simulated fills, and broker-neutral trading—now enhanced with premium data from Databento. Article content This collaboration aims to shift the paradigm in quant infrastructure, delivering institutional standards for data fidelity, latency, and developer ergonomics—positioning Tickblaze and Databento as the go-to stack for systematic trading. Article content About Tickblaze Article content Tickblaze, winner of Best Automated Trading Software and Best Hybrid Trading Solution at the Benzinga Fintech Awards, is redefining trading with its hybrid, multi-asset, broker-neutral platform. Built for institutions and now accessible to retail traders, Tickblaze offers integrated market data, C# and Python scripting, and advanced tools for discretionary and automated trading. Serving traders, brokers, prop firms, and hedge funds, Tickblaze combines award‑winning technology with a dynamic, open‑source community. Article content Article content Article content Article content Article content
National Post
35 minutes ago
- National Post
Manzil Expands Shariah-Compliant Investment Solutions to American Muslims with Alpaca
Article content NEW YORK & DALLAS — Manzil Investment Advisors LLC, an SEC-registered investment advisor and subsidiary of Manzil, a Canadian Islamic fintech startup, recently announced the launch of Manzil Invest USA, a new digital platform offering Shariah-compliant investment solutions specifically tailored for the American Muslim community. The platform is powered by a strategic partnership with Alpaca, a self-clearing broker-dealer and brokerage infrastructure API offering Shariah-compliant financial products. Article content With this launch, Manzil provides customers with access to a wide range of pre-determined halal investment strategies, furthering their mission to simplify investing and saving for Muslims across North America. Article content 'There are several million Muslims in the USA, many of whom feel excluded from the financial tools and advantages that their peers have access to,' stated Dr. Mohamad Sawwaf, Group CEO of Manzil. 'Muslims want to invest, but only about a third of the stocks in the S&P 500 are compliant with our beliefs. In the absence of a platform like Manzil Invest USA, many Muslims may sit out of the public stock market entirely.' By offering expertly managed and diversified portfolios that align with their customers' investment goals and risk tolerance, Manzil aims to remove any complexities for customers who are new to public equities. To ensure compliance with both Islamic and ethical investing principles, all securities are pre-screened by Manzil using the Accounting and Auditing Organization for Islamic Financial Institutions (AAOIFI) standards and further filtered through the American Friends Screening Committee (AFSC) criteria. Article content 'Our partnership with Manzil underscores Alpaca's commitment to fostering financial innovation and accessibility,' said Yoshi Yokokawa, CEO and Co-founder of Alpaca. 'We are excited to support Manzil's vision for inclusive finance by providing the infrastructure they need to deliver Shariah-compliant investment opportunities to millions of Muslims in the United States.' Article content Additionally, the platform provides educational resources to help users make informed financial decisions and plan for the future. Article content The Manzil Invest USA platform is now available for download in both the Apple App Store and Google Play Store. Article content About Alpaca Article content Alpaca is a US-headquartered self-clearing broker-dealer and brokerage infrastructure for stocks, ETFs, options, fixed income, and 24/5 trading– raising over USD170 million in funding. Alpaca is backed by top-tier investors globally, including Portage Ventures, Spark Capital, Tribe Capital, Social Leverage, Horizons Ventures, Unbound, SBI Group, Derayah Financial, Elefund, and Y Combinator. Article content About Manzil Article content Manzil is Canada's first AAOIFI-member Islamic FinTech company, providing Shariah-compliant mortgages, investments, wills, and savings solutions. Founded on the principles of financial justice and community empowerment, Manzil is committed to delivering inclusive, ethical financial alternatives tailored to Muslim consumers. Article content Alpaca does not make any representation that its products or services are Shariah-compliant. Customers are solely responsible for determining whether any offering meets their own Shariah requirements. Options trading is not suitable for all investors due to its inherent high risk, which can potentially result in significant losses. Please read Article content / Article content Article content Article content Article content
National Post
35 minutes ago
- National Post
Health Canada Approves WELLEX for Human Clinical Trial, Investigating Natural Cervical Health Supplement Papillex®
Article content TORONTO — WELLEX, in collaboration with Natural Products Canada, is pleased to announce that Health Canada has granted approval to proceed with a human clinical trial on its flagship product, Papillex®. This trial marks a major step forward in the company's commitment to supporting women's health with evidence-based natural health products. Article content The approved 18-month study will assess the nutritional support potential of Papillex® in individuals with persistent HPV infections. The trial design was developed with input from Dr. Hui (Amy) Chen, a gynecologic oncologist at the University of California, Davis, and will be conducted by KGK Science, a leading North American contract research organization with over 28 years of clinical research experience. KGK also led the successful submission to Health Canada, securing the necessary approval to initiate the clinical trial. Article content This milestone builds on the success of a previously completed observational study on Papillex® and represents WELLEX's dedication to rigorous scientific research in the field of cervical health. The trial is intended to provide further insights into the role of targeted nutritional support in immune and cervical health—an area of significant public health interest. Article content 'This approval from Health Canada is a meaningful milestone for our team and for the thousands of women seeking proactive, natural support for their cervical health, especially in cases of HPV persistence,' says Dr. Elizabeth Goldspink, ND, founder of WELLEX. 'Our goal has always been to bring trustworthy, evidence-informed solutions to the forefront, and this human clinical trial reflects our unwavering commitment to that mission.' Article content 'We're excited to congratulate WELLEX on achieving Health Canada approval for their Papillex® human clinical trial — a significant milestone that demonstrates the caliber of innovation emerging from our Game Changers portfolio,' adds Shelley King, CEO, Natural Products Canada. 'WELLEX's evidence-based approach to women's health exemplifies how Canadian companies are capturing opportunities in the global bioeconomy. NPC invested in their work to transform their promising innovation into a market-ready solution, and we are thrilled that they have achieved this major step on their commercialization pathway.' Article content WELLEX currently offers a line of products formulated to support women's health, including Papillex®, Simplix®, IC Well, Endo Well, and PCO Well, which are available to healthcare professionals and clients across Canada and the U.S. The company remains focused on supporting clinical research and practitioner education as part of its long-term strategy. Article content About WELLEX Article content WELLEX is a Canadian company dedicated to advancing women's health. Founded by Dr. Elizabeth Goldspink, ND, WELLEX formulates research-informed natural health products designed to support women's health. All products are third-party tested and manufactured in GMP-certified facilities in North America. Article content is the driving force behind Canada's Natural Product Innovation Cluster–a strategic and diverse community focused on the development and commercialization of naturally-derived products and technologies in health and life sciences, natural resources, agriculture and agri-food, and sustainable bioproducts. As part of its role in the Cluster, NPC offers in-depth advice and a suite of commercialization programs to Canadian early-stage companies and research institutes; provides connections and innovation scouting services to corporations and investors; and leverages an investment fund ( Article content Nàdarra Ventures Article content ) to help develop and de-risk promising Canadian opportunities. NPC has received financial support from the Government of Canada's Strategic Innovation Fund, administered by the department of Innovation, Science and Economic Development, and the Centre of Excellence in Commercialization and Research (CECR) program, administered by the Networks of Centres of Excellence. Article content About KGK Science Article content KGK is a premier North American contract research organization (CRO), specializing in high-quality clinical research for nutraceuticals and other emerging health products. Since its founding in 1997, KGK has supported hundreds of companies in bringing innovative products to global markets through custom-designed clinical trials and effective claim substantiation strategies. In addition to clinical research, KGK also offers comprehensive regulatory support, and consulting services. The company has conducted over 400 clinical trials across more than 40 health indications and contributed to over 150 peer-reviewed publications. Article content Article content
